


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method for the treatment of inflammation, the method comprising, administering to a subject in need thereof, an effective amount of a compound of formula (I):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and ~~pharmaceutically active derivatives~~ thereof, wherein

A is a 5-8 membered heterocyclic ~~or carbocyclic~~ group, ~~wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;~~

X is S or O;

Y¹ and Y² are independently S or O;



Z is S or O;

R¹ is H, CN, carboxy, acyl, C₁-C₆-alkoxy, halogen, hydroxy, acyloxy, C₁-C₆-alkyl carboxy, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl alkoxy, alkoxycarbonyl, C₁-C₆-alkyl alkoxycarbonyl, aminocarbonyl, C₁-C₆-alkyl aminocarbonyl, acylamino, C₁-C₆-alkyl acylamino, ureido, C₁-C₆-alkyl ureido, amino, C₁-C₆-alkyl amino, ammonium, sulfonyloxy, C₁-C₆-alkyl sulfonyloxy, sulfonyl, C₁-C₆-alkyl sulfonyl, sulfinyl, C₁-C₆-alkyl sulfinyl, sulfanyl, C₁-C₆-alkyl sulfanyl, sulfonylamino, C₁-C₆-alkyl sulfonylamino or carbamate;

R^2 is selected from the group consisting of H, halogen, acyl, amino, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkyl carboxy, C_1 - C_6 -alkyl acyl, C_1 - C_6 -alkyl alkoxycarbonyl, C_1 - C_6 -alkyl aminocarbonyl, C_1 - C_6 -alkyl acyloxy, C_1 - C_6 -alkyl acylamino, C_1 - C_6 -alkyl ureido, C_1 - C_6 -alkyl amino, C_1 - C_6 -alkyl alkoxy, C_1 - C_6 -alkyl sulfanyl, C_1 - C_6 -alkyl sulfinyl, C_1 - C_6 -alkyl sulfonyl, C_1 - C_6 -alkyl sulfonylaminoaryl, aryl, C_3 - C_8 -cycloalkyl or heterocycloalkyl, C_1 - C_6 -alkyl aryl, C_2 - C_6 -alkenyl-aryl, C_2 - C_6 -alkynyl aryl, carboxy, cyano, hydroxy, C_1 - C_6 -alkoxy, nitro, acylamino, ureido, C_1 - C_6 -alkyl carbamate, sulfonylamino, sulfanyl, or sulfonyl;

n is 0, 1 or 2;

with the proviso that the following compounds are excluded:



wherein R^1 is a lower alkyl or aralkyl and R^2 is H or a halogen.


Claims 2-5 (Cancelled).

Claim 6 (Previously Presented): The method according to claim 1, wherein Y^1 and Y^2 are both oxygen.

Claim 7 (Previously Presented): The method according to claim 1, wherein n is 1 or 2 and R^1 and R^2 are both H.

Claim 8 (Previously Presented): The method according to claim 1, wherein, in the compound of formula (I), X is S, Y¹ and Y² are both O, and n is 0.

Claim 9 (Previously Presented): The method according to claim 1, whereby the compound of formula (I) is a thiazolidinone-vinyl fused-benzene of the formula (Ia)




wherein Y¹, R¹, R², Z and n are as above defined for the compound of formula (I);
 V and W are each, independently from each other, O, S or -NR³ wherein R³ is H or C₁-C₆ alkyl;

G is a C₁-C₅ alkylene or a C₁-C₅ alkenylene group;

o and m are each, independently from each other, 0 or 1; and


q is an integer from 0 to 4.

Claim 10 (Previously Presented): The method according to claim 9, whereby the thiazolidinone-vinyl fused-benzene has the formula (Ib):




wherein Y^1 , R^1 , R^2 , V , Z , W , m , n , o , q are as above defined in the compound of formula (Ia), and p is an integer from 1 to 4.

Claim 11 (Previously Presented): The method according to claim 9, whereby the thiazolidinone-vinyl fused-benzene has the formula (Ic):



wherein W , as well as R^1 and Y^1 , are as above defined in the compound of formula (Ia).

Claim 12 (Previously Presented): The method according to claim 9, whereby the thiazolidinone-vinyl fused-benzene has the formula (Id):



wherein R^1 , R^2 , Z and n are as above defined in formula (Ia); o is 0 or 1;

p is an integer from 1 to 4 and q is an integer from 0 to 4.

Claim 13 (Previously Presented): The method according to claim 9, wherein, in formula (Ia), Z is O, m is 0, n is 1, p is 1 or 2, q is 1, and R¹ and R² are each as above defined for the compound of formula (Ia).


Claim 14 (Previously Presented): The method according to claim 9, wherein, in formula (Ia), m is 1, n is 0, p is 1 or 2, q is 0, and R¹ and R² are each as above defined for the compound of formula (Ia).

Claim 15 (Previously Presented): The method according to claim 9, wherein, in formula (Ia), m is 0, n is 1, p is 1 or 2, q is 0, and R¹ and R² are each as defined above for the compound of formula (I).

Claim 16 (Previously Presented): The method according to claim 9, wherein, in formula (Ia), R¹ is halogen or hydrogen.

Claims 17-18 (Cancelled)


Claim 19 (Previously Presented): A thiazolidinone-vinyl fused-benzene according to formula (II-a):



wherein A is selected from the group consisting of dioxol, dioxin, dihydrofuran, (dihydro) furanyl, (dihydro)oxazinyl, pyridinyl, isooxazolyl, oxazolyl (dihydro)naphthalenyl, pyrimidinyl, triazolyl, imidazolyl, pyrazinyl, thiazolidinyl, thiadiazolyl, and oxadiazolyl;

R² is selected from the group consisting of H, halogen, acyl, amino, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkenyl, C₁-C₆-alkyl carboxy, C₁-C₆-alkyl acyl, C₁-C₆-alkyl alkoxy, C₁-C₆-alkyl aminocarbonyl, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl acylamino, C₁-C₆-alkyl ureido, C₁-C₆-alkyl carbamate, C₁-C₆-alkyl amino, C₁-C₆-alkyl alkoxy, C₁-C₆-alkyl sulfanyl, C₁-C₆-alkyl sulfinyl, C₁-C₆-alkyl sulfonyl, C₁-C₆-alkyl sulfonylaminoaryl, aryl, C₃-C₈-cycloalkyl or heterocycloalkyl, C₁-C₆-alkyl aryl, C₂-C₆-alkenyl-aryl, C₂-C₆-alkynyl aryl, carboxy, cyano, hydroxy, C₁-C₆-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl.

Claim 20 (Currently Amended): A thiazolidinone-vinyl fused-benzene according to formula (II):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

Y^1 is S or O;

Z is S or O;

R¹ is H, CN, carboxy, acyl, C₁-C₆-alkoxy, halogen, hydroxy, acyloxy, C₁-C₆-alkyl carboxy, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl alkoxy, alkoxycarbonyl, C₁-C₆-alkyl

alkoxycarbonyl, aminocarbonyl, C₁-C₆-alkyl aminocarbonyl, acylamino, C₁-C₆-alkyl acylamino, ureido, C₁-C₆-alkyl ureido, amino, C₁-C₆-alkyl amino, ammonium, sulfonyloxy, C₁-C₆-alkyl sulfonyloxy, sulfonyl, C₁-C₆-alkyl sulfonyl, sulfinyl, C₁-C₆-alkyl sulfinyl, sulfanyl, C₁-C₆-alkyl sulfanyl, sulfonylamino, C₁-C₆-alkyl sulfonylamino or carbamate;


R² is selected from the group consisting of H, halogen, acyl, amino, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkyl carboxy, C₁-C₆-alkyl acyl, C₁-C₆-alkyl alkoxycarbonyl, C₁-C₆-alkyl aminocarbonyl, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl acylamino, C₁-C₆-alkyl ureido, C₁-C₆-alkyl amino, C₁-C₆-alkyl alkoxy, C₁-C₆-alkyl sulfanyl, C₁-C₆-alkyl sulfinyl, C₁-C₆-alkyl sulfonyl, C₁-C₆-alkyl sulfonylaminoaryl, aryl, C₃-C₈-cycloalkyl or heterocycloalkyl, C₁-C₆-alkyl aryl, C₂-C₆-alkenyl-aryl, C₂-C₆-alkynyl aryl, carboxy, cyano, hydroxy, C₁-C₆-alkoxy, nitro, acylamino, ureido, C₁-C₆-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl;

n is 0 or 1.

Claim 21 (Previously Presented): The thiazolidinone-vinyl fused-benzene according to claim 20, wherein Y¹ is O.

Claim 22 (Previously Presented): The thiazolidinone-vinyl fused-benzene according to claim 20, wherein R¹ is selected from the group consisting of C₁-C₆-alkyl, C₁-C₆-alkyl aryl, aryl, C₃-C₈-cycloalkyl or heterocycloalkyl, C₁-C₆-alkyl aryl, C₂-C₆-alkenyl-aryl and C₂-C₆-alkynyl aryl.

Claim 23 (Previously Presented): A thiazolidinone-vinyl fused-benzene according to formula (III):




as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, and wherein

R¹ is H, CN, carboxy, acyl, C₁-C₆-alkoxy, halogen, hydroxy, acyloxy, C₁-C₆-alkyl carboxy, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl alkoxy, alkoxycarbonyl, C₁-C₆-alkyl alkoxycarbonyl, aminocarbonyl, C₁-C₆-alkyl aminocarbonyl, acylamino, C₁-C₆-alkyl acylamino, ureido, C₁-C₆-alkyl ureido, amino, C₁-C₆-alkyl amino, ammonium, sulfonyloxy, C₁-C₆-alkyl sulfonyloxy, sulfonyl, C₁-C₆-alkyl sulfonyl, sulfinyl, C₁-C₆-alkyl sulfinyl, sulfanyl, C₁-C₆-alkyl sulfanyl, sulfonylamino, C₁-C₆-alkyl sulfonylamino or carbamate;

R² is selected from the group consisting of H, halogen, acyl, amino, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkyl carboxy, C₁-C₆-alkyl acyl, C₁-C₆-alkyl alkoxycarbonyl, C₁-C₆-alkyl aminocarbonyl, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl acylamino, C₁-C₆-alkyl ureido, C₁-C₆-alkyl amino, C₁-C₆-alkyl alkoxy, C₁-C₆-alkyl sulfanyl, C₁-C₆-alkyl sulfinyl, C₁-C₆-alkyl sulfonyl, C₁-C₆-alkyl sulfonylaminoaryl, aryl, C₃-C₈-cycloalkyl or heterocycloalkyl, C₁-C₆-alkyl aryl, C₂-C₆-alkenyl-aryl, C₂-C₆-alkynyl aryl, carboxy, cyano, hydroxy, C₁-C₆-alkoxy, nitro, acylamino, ureido, C₁-C₆-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl.

Claim 24 (Previously Presented): A thiazolidinone-vinyl fused-benzene according any of formulae (IV), (V) and (VI):



wherein R^1 is selected from the group consisting of hydrogen, halogen, cyano, C_1 - C_6 -alkyl, C_1 - C_6 -alkoxy, acyl, and alkoxy carbonyl, and

R^2 is selected from the group consisting of H, halogen, acyl, amino, C_1 - C_6 -alkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkyl carboxy, C_1 - C_6 -alkyl acyl, C_1 - C_6 -alkyl alkoxy, C_1 - C_6 -alkyl aminocarbonyl, C_1 - C_6 -alkyl acyloxy, C_1 - C_6 -alkyl acylamino, C_1 - C_6 -alkyl ureido, C_1 - C_6 -alkyl amino, C_1 - C_6 -alkyl alkoxy, C_1 - C_6 -alkyl sulfanyl, C_1 - C_6 -alkyl sulfinyl, C_1 - C_6 -alkyl sulfonyl, C_1 - C_6 -alkyl sulfonylaminoaryl, aryl, C_3 - C_8 -cycloalkyl or heterocycloalkyl, C_1 - C_6 -alkyl aryl, C_2 - C_6 -alkenyl-aryl, C_2 - C_6 -alkynyl aryl, carboxy, cyano, hydroxy, C_1 - C_6 -alkoxy, nitro, acylamino, ureido, C_1 - C_6 -alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl.

Claim 25 (Previously Presented): The thiazolidinone-vinyl fused-benzene according to claim 19, selected from the group consisting of:

- 5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione,
- 5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3-thiazolidin-4-one,
- 5-(2,3-dihydro-1,4-benzodioxin-6-ylmethylene)-1,3-thiazolidine-2,4-dione,

5-(2,3-dihydro-1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,
5-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione,
5-[(9,10-dioxo-9,10-dihydroanthracen-2-yl)methylene]-1,3-thiazolidine-2,4-dione,
5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione,
(5Z)-5-(1,3-dihydro-2-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,
5-(1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,
5-[(4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-1,3-thiazolidine-
2,4-dione,
5-(1,3-benzodioxol-5-ylmethylene)-2-imino-1,3-thiazolidin-4-one,
5-Quinolin-6-ylmethylene-thiazolidine-2,4-dione,
5-Quinolin-6-ylmethylene-2-thioxo-thiazolidin-4-one,
2-Imino-5-quinolin-6-ylmethylene-thiazolidin-4-one,
5-(3-Methyl-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione,
5-(4-Phenyl-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,
5-(4-Dimethylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,
5-[(4-aminoquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,
5-[(4-piperidin-1-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,
5-[(4-morpholin-4-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,
5-{{4-(benzylamino)quinazolin-6-yl}methylene}-1,3-thiazolidine-2,4-dione,
5-{{4-(diethylamino)quinazolin-6-yl}methylene}-1,3-thiazolidine-2,4-dione,
5-{{4-[(pyridin-2-ylmethyl)amino]quinazolin-6-yl}methylene}-1,3-thiazolidine-2,4-
dione,
5-{{4-[(pyridin-3-ylmethyl)amino]quinazolin-6-yl}methylene}-1,3-thiazolidine-2,4-
dione,

ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-3-carboxylate,

ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-4-carboxylate,

tert-butyl-1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}-L-prolinate,

5-{[4-(4-methylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{[4-(4-pyrimidin-2-ylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-({4-[4-(4-fluorophenyl)piperidin-1-yl]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-{[4-(4-benzylpiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-({4-[4-(2-phenylethyl)piperidin-1-yl]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-{[4-(4-methylpiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{[4-(4-hydroxypiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-4-carboxylic acid,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-3-carboxylic acid,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-pyrrolidine-2-carboxylic acid,

5-(4-Methylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Methoxy-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione
2-Imino-5-(4-methylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one,
2-Imino-5-(4-piperidine-quinazolin-6-ylmethylene)-thiazolidin-4-one,
2-Imino-5-(4-dimethylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one,
5-(2-Methyl-2H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione,
5-(3-Methyl-3H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione,
5-(3-Ethyl-3H-benzoimidazol-5-ylmethylene)-thiazolidine-2,4-dione,
5-([1-(4-phenylbutyl)-1H-benzimidazol-6-yl]methylene)-1,3-thiazolidine-2,4-dione,
5-[(1-prop-2-yn-1-yl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,
5-[(1-{2-[4-(trifluoromethyl)phenyl] ethyl} -1H-benzimidazol-6-yl)methylene]-1,3-
thiazolidine-2,4-dione,
5-({1-[2-(4-hydroxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-
thiazolidine-2,4-dione,
methyl 4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-1-
yl}cyclohexanecarboxylate,
5-({1-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-
thiazolidine-2,4-dione,
5-({1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-benzimidazol-6-yl}methylene)-1,3-
thiazolidine-2,4-dione,
5-({1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-
thiazolidine-2,4-dione,
5-({1-[2-(4-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-
thiazolidine-2,4-dione,
5-({1-[4-(trifluoromethyl)benzyl]-1H-benzimidazol-6-yl }methylene)-1,3-
thiazolidine-2,4-dione,

4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-1-yl}cyclohexanecarboxylic acid,

5-[(1-isobutyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-({1-[2-(1,3-benzodioxol-4-yl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({1-[2-(2-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-1[1-(3,3-diphenylpropyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{[1-(2-methoxybenzyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{[1-(3-furylmethyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-[(1-propyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-Quinoxalin-6-ylmethylene-thiazolidine-2,4-dione,

5-Quinoxalin-6-ylmethylene-2-thioxo-thiazolidin-4-one,

2-Imino-5-quinoxalin-6-ylmethylene-thiazolidin-4-one,

5-Benzothiazol-6-ylmethylene-thiazolidine-2,4-dione,

5-(3-Methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

5-(2-Bromo-3-methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

5-(3-bromo-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid ethyl ester,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid,

5-[3-(3-Oxo-3-piperidin-1-yl-propenyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione,

Methyl 1-((3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)prolinate,

Methyl 1-((3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-D-prolinate,

(5-{3-[(3-oxo-3-pyrrolidin-1-ylprop-1-en-1-yl)-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-morpholin-4-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

Methyl 1-(3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-L-prolinate,

N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-methylacrylamide,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-ethyl-N-(2-hydroxyethyl)acrylamide,

N-cyclobutyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide,

5-({3-[3-azetidin-1-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-(1,3-dihydro-2H-isoindol-2-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-azepan-1-yl-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-piperidin-1-ylacrylamide,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-(pyridin-3-ylmethyl)acrylamide,

N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide,

5-({3-[3-(4-methylpiperazin-1-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

N-cycloheptyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide,

5-({3-[3-(2,5-dihydro-1H-pyrrol-1-yl)-3-oxoprop-1-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

N-cyclopentyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid ethyl ester,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid,
5-[3-(3-Oxo-3-piperidin-1-yl-propyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione,

6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester,

5-(3,4-Dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,
5-(4-Benzoyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Acetyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,
6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester,

[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-acetic acid methyl ester,

N-Benzyl-2-[6-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl]-acetamide,

5-(4-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Benzyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(2-Chloro-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

5-(3-Amino-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione,

5-(3-Phenylethynyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

5-Benzo[1,2,5]thiadiazol-5-ylmethylene-thiazolidine-2,4-dione,

5-Benzo[1,2,5]oxadiazol-5-ylmethylene-thiazolidine-2,4-dione,

5-(2-Methyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione,

5-(2-Carboxymethyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione,

5-(3-Bromo-2-fluoro-2,3-dihydro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione,

and

5-(2-Fluoro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione.


Claim 26 (Previously Presented): A method of preparing a medicament, comprising, contacting the thiazolidinone-vinyl fused-benzene according to claim 19, with one or more pharmaceutically acceptable additives.

Claim 27 (Previously Presented): A pharmaceutical composition, comprising at least one thiazolidinone-vinyl fused-benzene according to claim 19, and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 28 (Currently Amended): A method for the treatment of ~~an inflammatory~~ disease inflammation, the method comprising administering to a subject in need thereof, an effective amount of the thiazolidinone-vinyl fused-benzene according to claim 19.


Claims 29-34 (Cancelled)

Claim 35 (Previously Presented): A method of preparing a thiazolidinone-vinyl fused-benzene of formula (II), according to claim 20, comprising the following step:



wherein R^1 , R^2 , Y_1 , Z and n are as above defined in formula (II).

Claim 36 (Previously Presented): A method of preparing a thiazolidinone-vinyl fused-benzene of formula (III), according to claim 23, comprising the following step:




wherein R^1 , R^2 are as above defined for formula (III), and

Y^1 is O, S or NH.

Claim 37 (Currently Amended): A composition, comprising, a pharmaceutically acceptable carrier, diluent or excipient and at least one [[a]] compound according to formula

(I):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts ~~and pharmaceutically active derivatives~~ thereof, wherein

A is a 5-8 membered heterocyclic ~~or carbocyclic~~ group, ~~wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;~~

X is S or O;

Y^1 and Y^2 are independently S or O;



Z is S or O;

R¹ is H, CN, carboxy, acyl, C₁-C₆-alkoxy, halogen, hydroxy, acyloxy, C₁-C₆-alkyl carboxy, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl alkoxy, alkoxycarbonyl, C₁-C₆-alkyl alkoxycarbonyl, aminocarbonyl, C₁-C₆-alkyl aminocarbonyl, acylamino, C₁-C₆-alkyl acylamino, ureido, C₁-C₆-alkyl ureido, amino, C₁-C₆-alkyl amino, ammonium, sulfonyloxy, C₁-C₆-alkyl sulfonyloxy, sulfonyl, C₁-C₆-alkyl sulfonyl, sulfinyl, C₁-C₆-alkyl sulfinyl, sulfanyl, C₁-C₆-alkyl sulfanyl, sulfonylamino, C₁-C₆-alkyl sulfonylamino or carbamate;

R² is selected from the group consisting of H, halogen, acyl, amino, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkyl carboxy, C₁-C₆-alkyl acyl, C₁-C₆-alkyl alkoxycarbonyl, C₁-C₆-alkyl aminocarbonyl, C₁-C₆-alkyl acyloxy, C₁-C₆-alkyl acylamino, C₁-C₆-alkyl ureido, C₁-C₆-alkyl amino, C₁-C₆-alkyl alkoxy, C₁-C₆-alkyl sulfanyl, C₁-C₆-alkyl sulfinyl, C₁-C₆-alkyl sulfonyl, C₁-C₆-alkyl sulfonylaminoaryl, aryl, C₃-C₈-cycloalkyl or heterocycloalkyl, C₁-C₆-alkyl aryl, C₂-C₆-alkenyl-aryl, C₂-C₆-alkynyl aryl, carboxy, cyano, hydroxy, C₁-C₆-alkoxy, nitro, acylamino, ureido, C₁-C₆-alkyl carbamate, sulfonylamino, sulfanyl, or sulfonyl;

n is 0, 1 or 2;

with the proviso that the following compounds are excluded:



wherein R¹ is a lower alkyl or aralkyl and R² is H or a halogen.